Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus 5-fluorouracil/leucovorin beyond progression on fruquintinib in metastatic colorectal cancer
ChiCTR2000032640Phase 2Recruiting
- Sponsor
- National Center for Biotechnology
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by National Center for Biotechnology. Primary endpoints: Recommended phase II dose and 6-month overall survival rate. Started Apr 2020; status: recruiting.
02
Drugs
fruquintinibfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000032640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032640.